Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin’s lymphoma: results of a prospective randomized controlled trial

Witzens-Harig, Mathias; Reiz, Monika; Heiß, Christiane; Benner, Axel; Hensel, Manfred; Neben, Kai; Dreger, Peter; Kraemer, Alwin; Ho, Anthony
January 2009
Annals of Hematology;Jan2009, Vol. 88 Issue 1, p51
Academic Journal
The introduction of rituximab into the primary treatment of malignant lymphomas of the B cell lineage has had a major impact on the management of these diseases. In addition, prolonged exposure to rituximab as maintenance therapy has been beneficial in patients with follicular lymphoma and mantle cell lymphoma. For the individual patient, the effect of any prolonged antitumor therapy on the quality of life (QoL) is a very important question. However, so far, the question whether rituximab maintenance therapy may impair QoL in patients with non-Hodgkin’s lymphoma remains unanswered. To investigate this subject, we have performed a prospective randomized trial of rituximab maintenance therapy (8 cycles rituximab 375 mg/m2 every 3 months) versus observation in patients with CD20+B cell non-Hodgkin’s lymphoma in our institution. Between July 2002 and December 2005, 122 patients were included into the trial. QoL was assessed with the standardized questionnaires EORTC-QLQ-C30, EuroQol-5D, and EuroQol-5D (VAS) in 91 patients. After statistical analysis with the exact Wilcoxon rank sum test, we found no significant differences of the QoL between the rituximab treatment group and the observation group. We conclude that rituximab maintenance therapy seems to be safe and does not impair quality of life in this patient population.


Related Articles

  • Antineoplastics/doxorubicin.  // Reactions Weekly;Oct2015, Vol. 1575 Issue 1, p22 

    An abstract of the article "Upfront intensification incorporating dose-dense rituximab and high-dose MTX to chop-14 in young high-risk aggressive B-cell lymphoma patients," by T. Strusmann and colleagues is presented.

  • Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ennishi, D.; Asai, H.; Maeda, Y.; Shinagawa, K.; Ikeda, K.; Yokoyama, M.; Terui, Y.; Takeuchi, K.; Yoshino, T.; Matsuo, K.; Hatake, K.; Tanimoto, M. // Annals of Oncology;Jun2010, Vol. 21 Issue 6, p1217 

    Background: A recent laboratory study indicated that statins impaired the antitumor effects of rituximab by inducing conformational changes in CD20. Although these findings raised significant concerns about statin use during rituximab treatment, their clinical significance is unclear.

  • Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients. J. Valencak; F. Weihsengruber; K. Rappersberger; F. Trautinger; A. Chott; B. Streubel; L. Muellauer; M. Der-Petrossian; C. Jonak; M. Binder; M. Raderer // Annals of Oncology;Feb2009, Vol. 20 Issue 2, p326 

    Background: We have carried out a retrospective analysis to evaluate the therapeutic value of the anti-CD20 antibody rituximab in 16 consecutive patients with primary cutaneous CD20 B-cell lymphomas. Patients and methods: Sixteen patients (4 females, 12 males) with a median age of 54 years...

  • Rituximab.  // Reactions Weekly;5/14/2011, Issue 1351, p38 

    The article describes the case of a 30-year-old man who developed late-onset neutropenia after receiving rituximab and radiotherapy for primary mediastinal B-cell lymphoma.

  • Primary diffuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic options. Aviv, A.; Tadmor, T.; Polliack, A. // Annals of Oncology;Sep2013, Vol. 24 Issue 9, p2236 

    Primary breast lymphoma is a rare form of non-Hodgkin lymphoma with some distinct clinical features. The most common histopathological type is diffuse large B-cell lymphoma (DLBCL), but other less frequent subtypes are also encountered. In this review, we describe the characteristics of primary...

  • Radiotherapy beats lymphoma.  // Dermatology Times;Feb2008, Vol. 29 Issue 2, p76 

    The article cites a retrospective study conducted by Dutch researchers, which suggests that radiotherapy is effective for patients with primary cutaneous B-cell lymphomas. However, the researchers found that more aggressive treatment is required for lesions on the leg. The researchers used a...

  • Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. Vacirca, Jeffrey; Acs, Peter.; Tabbara, Imad; Rosen, Peter.; Lee, Peter; Lynam, Eric // Annals of Hematology;Mar2014, Vol. 93 Issue 3, p403 

    Patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) are treated with salvage regimens and may be considered for high-dose chemotherapy and autologous stem cell transplantation if disease is chemosensitive. Bendamustine is active in indolent B cell lymphomas and chronic...

  • CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Schmitz, N.; Zeynalova, S.; Glass, B.; Kaiser, U.; Cavallin-Stahl, E.; Wolf, M.; Haenel, M.; Loeffler, M.; Truemper, L.; Pfreundschuh, M. // Annals of Oncology;May2012, Vol. 23 Issue 5, p1267 

    Background: To describe incidence, risk factors, and influence of treatment on occurrence of central nervous system (CNS) relapse or progression in younger patients with aggressive B-cell lymphoma. Patients and methods: We analyzed 2210 patients with aggressive B-cell lymphoma treated on various...

  • B-Cell Lymphoma With Intermediate- to High-Grade Features and Different Immunophenotypic Profiles Involving Separate Anatomic Sites With a Good Response to R-CHOP. Ron Lee; Christine Green; O. Negrea; Sarah Dodson; Sara Farrell; James Hewitt; Toni Jago; Chris Ramsey; Tracey Cato; Eric Crawford; Donald Henley; Mary Phelan; Nicholas Potter // Laboratory Medicine;Feb2009, Vol. 40 Issue 2, p79 

    The occurrence of B-cell lymphoma with intermediate- to high-grade features and different immunophenotypic profiles involving separate anatomic sites is uncommon. We describe such a case and present results of ancillary studies that characterized this B-cell lymphoma. The patient was treated...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics